EMA Authorised: Mepact (mifamurtide) — Esteve Pharmaceuticals, S.A.

View source ↗

Summary

The European Medicines Agency authorised Mepact (mifamurtide) for the treatment of osteosarcoma; the marketing authorization holder is Esteve Pharmaceuticals, S…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteosarcoma

Drugs mentioned

• Mepact (mifamurtide)

Snippet

Status: Authorised. Therapeutic area: Osteosarcoma. MAH: Esteve Pharmaceuticals, S.A.. Decision date: 18/12/2025